| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/19/2002 | EP1214101A1 Method for detecting and killing epithelial cancer cells |
| 06/19/2002 | EP1214096A2 Taxane prodrugs |
| 06/19/2002 | EP1214095A1 Use of anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 06/19/2002 | EP1214092A2 Method of potentiating chemotherapy and treating solid tumors |
| 06/19/2002 | EP1214091A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 06/19/2002 | EP1214090A2 Novel uses of mammalian ccr6 receptors and related reagents |
| 06/19/2002 | EP1214087A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| 06/19/2002 | EP1214086A2 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 06/19/2002 | EP1214078A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 06/19/2002 | EP1214074A2 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/19/2002 | EP1214067A1 Methods for treating cell proliferative disorders including cancer |
| 06/19/2002 | EP1214066A1 Formation of nanometer-scale structures |
| 06/19/2002 | EP1214064A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 06/19/2002 | EP1214063A1 Method of treating cancer using tetraethyl thiuram disulfide |
| 06/19/2002 | EP1214062A2 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| 06/19/2002 | EP1214060A2 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| 06/19/2002 | EP1214059A2 Surface modified particulate compositions of biologically active substances |
| 06/19/2002 | EP1214057A1 Vascular coating composition |
| 06/19/2002 | EP1214056A1 Topical suspension formulations containing ciprofloxacin and dexamethasone |
| 06/19/2002 | EP1214048A1 Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
| 06/19/2002 | EP1214041A2 Combination therapy for the treatment of sepsis |
| 06/19/2002 | EP1214039A2 Methods and compositions for preventing and treating urinary tract disorders |
| 06/19/2002 | EP1214038A2 Methods and compositions for preventing and treating prostate disorders |
| 06/19/2002 | EP1213971A1 Improving condition of elderly pets |
| 06/19/2002 | EP0900275B1 Methods and reagents for modulating apoptosis |
| 06/19/2002 | EP0892643B1 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 06/19/2002 | EP0877750B1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents |
| 06/19/2002 | EP0852497B1 Use of prostane derivatives and the combination thereof with antibiotics in the treatment of bacterial infections |
| 06/19/2002 | EP0754061B1 New oral pharmaceutical dosage form |
| 06/19/2002 | EP0634932B1 Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| 06/19/2002 | CN1354749A Use of selective antagonists of 1b-adrenergic receptor for improvement of sexual dysfunction |
| 06/19/2002 | CN1354676A Amnotetralin derivative for therapy of cardiovascular diseases |
| 06/19/2002 | CN1354673A New dialysis method |
| 06/19/2002 | CN1354667A Use of camptotheicin derivatives with reduced gastrointestinal toxicity |
| 06/19/2002 | CN1354663A Sulfonamide and sulfamide substituted imidazoquinolines |
| 06/19/2002 | CN1354661A Novel method of treatment |
| 06/19/2002 | CN1354658A New use of compounds as antibacterial agents |
| 06/19/2002 | CN1354657A EGF-R antagonists for treating hypersecretion of mucus in lungs |
| 06/19/2002 | CN1354655A Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
| 06/19/2002 | CN1354654A Transdermal therapeutic system with neutralized pressure sensitiivty acrylic adhesive patch |
| 06/19/2002 | CN1354640A Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 06/19/2002 | CN1353990A Preparation for analgesia and anesthesia or curing drug dependence |
| 06/18/2002 | US6408051 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus |
| 06/18/2002 | US6407140 Autoimmune diseases, graft versus host disease and organ transplant surgery; pyrazole derivative mixture |
| 06/18/2002 | US6407135 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
| 06/18/2002 | US6407133 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 06/18/2002 | US6407125 Administering 2-carboxypyridine derivative to treat skin, respiratory system, and immune disorders; anticarcinogenic, antiinflammatory and antiviral agents; deactivating metal-protein complexes |
| 06/18/2002 | US6407088 Method of analgesia |
| 06/18/2002 | US6407071 Method and composition for treating malignant cells |
| 06/18/2002 | US6407058 Phosphorylation of serine or threonine |
| 06/18/2002 | US6406861 Viral diseases and immunogens |
| 06/18/2002 | US6406722 Topical; mixture containing olive oil and beeswax |
| 06/18/2002 | US6406716 Comprising neuropathic pain-alleviating amount of anticonvulsant and anticonvulsant-potentiating amount of antagonist for n-methyl-d-aspartate receptor or substance that blocks major intracellular consequence of receptor activation |
| 06/13/2002 | WO2002046749A2 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | WO2002046477A2 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | WO2002046475A2 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 06/13/2002 | WO2002046461A2 Method for identifying modulators of transcription |
| 06/13/2002 | WO2002046426A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | WO2002046419A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/13/2002 | WO2002046418A2 Lipid-associated molecules |
| 06/13/2002 | WO2002046407A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | WO2002046406A2 Human transporter proteins, nucleic acid molecules encoding them,and uses thereof |
| 06/13/2002 | WO2002046404A2 Schizophrenia-related voltage-gated ion channel gene and protein |
| 06/13/2002 | WO2002046385A2 Enzymes |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046382A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 06/13/2002 | WO2002046240A1 Multicomponent compositions containing chitosan and methods of preparing same |
| 06/13/2002 | WO2002046230A2 G-protein coupled receptors |
| 06/13/2002 | WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | WO2002046216A2 Human sprouty-4 polypeptide |
| 06/13/2002 | WO2002046212A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | WO2002046181A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046172A2 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046162A1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors |
| 06/13/2002 | WO2002046141A2 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | WO2002045867A1 Method for producing a partial or complete active ingredient coating on and in implants and onplants |
| 06/13/2002 | WO2002045751A1 Compositions for the treatment of coccidiosis |
| 06/13/2002 | WO2002045750A1 Combination drugs |
| 06/13/2002 | WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | WO2002045748A1 Ocular tension-lowering compositions for topical administration |
| 06/13/2002 | WO2002045739A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045720A1 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 06/13/2002 | WO2002045717A1 Lometrexol combination therapy |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045710A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | WO2002045708A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 06/13/2002 | WO2002045704A2 Prevention and treatment of tachyphylactic response |
| 06/13/2002 | WO2002045694A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045693A1 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 06/13/2002 | WO2002045682A1 Particulate inhalation carrier |
| 06/13/2002 | WO2002045661A1 Use of moulding compounds for producing treatment devices |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002045525A2 Aged companion pet diet |
| 06/13/2002 | WO2002030906B1 Anti-tumour compounds |
| 06/13/2002 | WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |